Integrated Advisors Network LLC boosted its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 471.1% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 12,907 shares of the exchange traded fund’s stock after buying an additional 10,647 shares during the period. Integrated Advisors Network LLC’s holdings in SPDR S&P Biotech ETF were worth $2,035,000 as of its most recent SEC filing.
Several other large investors have also recently bought and sold shares of XBI. Bank of America Corp DE lifted its stake in SPDR S&P Biotech ETF by 13.3% in the 1st quarter. Bank of America Corp DE now owns 14,518,027 shares of the exchange traded fund’s stock worth $1,854,388,000 after acquiring an additional 1,700,851 shares in the last quarter. Main Street Research LLC grew its stake in SPDR S&P Biotech ETF by 57.4% during the 1st quarter. Main Street Research LLC now owns 567,479 shares of the exchange traded fund’s stock valued at $72,484,000 after acquiring an additional 206,953 shares in the last quarter. Strs Ohio increased its holdings in shares of SPDR S&P Biotech ETF by 4.9% in the 1st quarter. Strs Ohio now owns 410,500 shares of the exchange traded fund’s stock valued at $52,433,000 after purchasing an additional 19,300 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in shares of SPDR S&P Biotech ETF by 145.7% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 314,224 shares of the exchange traded fund’s stock valued at $49,726,000 after purchasing an additional 186,314 shares during the period. Finally, Annex Advisory Services LLC increased its holdings in shares of SPDR S&P Biotech ETF by 4.6% in the 3rd quarter. Annex Advisory Services LLC now owns 266,485 shares of the exchange traded fund’s stock valued at $42,019,000 after purchasing an additional 11,723 shares during the period.
SPDR S&P Biotech ETF Price Performance
NYSEARCA XBI opened at $152.78 on Thursday. The company has a 50 day simple moving average of $157.66 and a 200-day simple moving average of $147.55. The firm has a market capitalization of $10.55 billion, a price-to-earnings ratio of 11.47 and a beta of 0.83. SPDR S&P Biotech ETF has a 52-week low of $106.30 and a 52-week high of $169.89.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Read More
- Five stocks we like better than SPDR S&P Biotech ETF
- GM Beat and Added a $20 Billion Buyback—Why Did the Stock Fall?
- Intercepting Growth: Karman Secures $218M Lockheed Martin Deal
- Tech Stocks Took a Hit—These 2 Pharma Stocks Are Near New Highs
- Chip Stocks Have Pulled Back—Here’s How 3 Semiconductor ETFs Stack Up for Investors
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
